Literature DB >> 17981041

Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Thomas A Munro1, Katharine K Duncan, Wei Xu, Yulin Wang, Lee-Yuan Liu-Chen, William A Carlezon, Bruce M Cohen, Cécile Béguin.   

Abstract

Protection of salvinorin B as standard alkoxyalkyl ethers yielded highly potent kappa opioid receptor agonists. Ethoxymethyl ether 6 is among the most potent and selective kappa agonists reported to date. Fluoroethoxymethyl ether 11 is the first potent, selective fluorinated kappa ligand, with potential use in MRI and PET studies. Further enlargement of the alkoxy group, alkylation of the acetal carbon, or heteroatom substitution all reduced activity. These protecting groups may prove useful in related work not only by enabling the use of harsher synthetic conditions, but potentially by optimizing the potency of the products.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981041      PMCID: PMC2568987          DOI: 10.1016/j.bmc.2007.10.067

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

Review 1.  Analgesic substances derived from natural products (natureceuticals).

Authors:  Christopher R McCurdy; Stephen S Scully
Journal:  Life Sci       Date:  2005-10-10       Impact factor: 5.037

2.  Synthesis of new phorbol derivatives having ethereal side chain and evaluation of their anti-HIV activity.

Authors:  Yuji Matsuya; Zhong Yu; Naoki Yamamoto; Masao Mori; Haruo Saito; Makoto Takeuchi; Mamiko Ito; Hideo Nemoto
Journal:  Bioorg Med Chem       Date:  2005-07-15       Impact factor: 3.641

3.  Synthesis of salvinorin A analogues as opioid receptor probes.

Authors:  Kevin Tidgewell; Wayne W Harding; Anthony Lozama; Howard Cobb; Kushal Shah; Pavitra Kannan; Christina M Dersch; Damon Parrish; Jeffrey R Deschamps; Richard B Rothman; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2006-06       Impact factor: 4.050

4.  Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.

Authors:  David Y W Lee; Vishnu V R Karnati; Minsheng He; Lee-Yuan Liu-Chen; Leelakrishna Kondaveti; Zhongze Ma; Yulin Wang; Yong Chen; Cecile Beguin; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem Lett       Date:  2005-08-15       Impact factor: 2.823

5.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Thomas A Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

6.  Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).

Authors:  Cécile Béguin; Michele R Richards; Yulin Wang; Yong Chen; Lee-Yuan Liu-Chen; Zhongze Ma; David Y W Lee; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem Lett       Date:  2005-06-02       Impact factor: 2.823

7.  Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Authors:  William A Carlezon; Cécile Béguin; Jennifer A DiNieri; Michael H Baumann; Michele R Richards; Mark S Todtenkopf; Richard B Rothman; Zhongze Ma; David Y-W Lee; Bruce M Cohen
Journal:  J Pharmacol Exp Ther       Date:  2005-10-13       Impact factor: 4.030

8.  11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons.

Authors:  Peter S Talbot; Raj Narendran; Eduardo R Butelman; Yiyun Huang; Kim Ngo; Mark Slifstein; Diana Martinez; Marc Laruelle; Dah-Ren Hwang
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

9.  A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A.

Authors:  Kevin Tidgewell; Wayne W Harding; Mark Schmidt; Kenneth G Holden; Daryl J Murry; Thomas E Prisinzano
Journal:  Bioorg Med Chem Lett       Date:  2004-10-18       Impact factor: 2.823

10.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

View more
  26 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

2.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

3.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

4.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

5.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

6.  Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

Authors:  Katherine M Prevatt-Smith; Kimberly M Lovell; Denise S Simpson; Victor W Day; Justin T Douglas; Peter Bosch; Christina M Dersch; Richard B Rothman; Bronwyn Kivell; Thomas E Prisinzano
Journal:  Medchemcomm       Date:  2011-12       Impact factor: 3.597

Review 7.  Neoclerodanes as atypical opioid receptor ligands.

Authors:  Thomas E Prisinzano
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

8.  Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.

Authors:  Alexander M Sherwood; Samuel E Williamson; Rachel S Crowley; Logan M Abbott; Victor W Day; Thomas E Prisinzano
Journal:  Org Lett       Date:  2017-09-14       Impact factor: 6.005

9.  CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.

Authors:  Donna L McGovern; Philip D Mosier; Bryan L Roth; Richard B Westkaemper
Journal:  J Mol Graph Model       Date:  2010-01-04       Impact factor: 2.518

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.